68Ga-PSMA PET/CT用于评估转移性前列腺癌患者接受紫杉烷类化疗的疗效反应及预后预测
回顾性评估37例转移性前列腺癌患者在接受紫杉烷类化疗(多西他赛或卡巴他赛)前后行68Ga-PSMA-11 PET/CT,PSMA总肿瘤体积下降至少30%定义为PSMA反应。PSMA反应与生化反应一致率高(ϕ=0.89,P<0.0001),PSMA反应组总生存显著长于无反应组(中位未达到 vs 12个月,HR 0.10,95%CI 0.03-0.39,P=0.001)。
要点
- PSMA总肿瘤体积下降≥30%定义的PSMA反应与生化反应一致率高达35/37(ϕ=0.89)。
- PSMA反应组较无反应组总生存显著延长(中位未达到 vs 12个月,HR 0.10)。
- mCRPC亚组中PSMA反应组12个月总生存率100% vs 52%(P=0.011)。
核心结论
- 这项回顾性分析提示,68Ga-PSMA-11 PET/CT是评估转移性前列腺癌紫杉烷类化疗疗效的有前景的影像方法。
- PSMA表达变化可能作为总生存的预测生物标志物,有助于个体化治疗和筛选适合临床试验的患者。
研究设计与样本
- 回顾性评估37例转移性激素敏感性前列腺癌或转移性去势抵抗性前列腺癌(mCRPC)患者。
- 患者在接受紫杉烷类化疗(多西他赛或卡巴他赛)末次周期后行68Ga-PSMA-11 PET/CT,两次扫描间未更改治疗。
- 生化反应定义为前列腺特异性抗原不可测或较基线下降至少50%。
- PSMA反应定义为PSMA总肿瘤体积(PSMA-TV)较基线下降至少30%,否则为PSMA无反应。
主要发现
- 队列包括8例(22%)转移性激素敏感性前列腺癌和29例(78%)mCRPC患者;21例接受多西他赛,16例接受卡巴他赛(中位6周期,四分位距5-8周期)。
- 37例中18例达到生化反应;基于PSMA总肿瘤体积,PSMA PET/CT反应与生化反应在35/37例中一致(ϕ=0.89,P<0.0001)。
- 37例中18例为PSMA反应(6例完全缓解,12例部分缓解),19例为PSMA无反应(17例疾病进展,2例疾病稳定)。
- 中位随访23个月,全人群PSMA反应组总生存显著长于无反应组(中位总生存未达到 vs 12个月;HR 0.10;95%CI 0.03-0.39;P=0.001)。
- mCRPC亚组中亦观察到总生存差异(中位22 vs 12个月;HR 0.22;95%CI 0.06-0.82;P=0.023),12个月总生存率PSMA反应组100% vs 无反应组52%(P=0.011)。
关键数值与推荐
- 生化反应:前列腺特异性抗原不可测或较基线下降至少50%。
- PSMA反应:PSMA总肿瘤体积较基线下降至少30%。
- PSMA PET/CT反应与生化反应一致性:35/37例(ϕ=0.89,P<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to evaluate the role of PET targeting the prostate-specific membrane antigen (PSMA) for response assessment in metastatic prostate cancer (PCa) patients treated with taxane-based chemotherapy (docetaxel or cabazitaxel) and its predictive value on patient outcome. Methods: We retrospectively evaluated 37 patients with metastatic hormone-sensitive PCa or metastatic castration-resistant PCa (mCRPC) who underwent 68Ga-PSMA-11 PET/CT at baseline and after the last cycle of taxane-based chemotherapy (docetaxel or cabazitaxel) without treatment modification between scans. Biochemical response (BR) was defined as an undetectable or at least 50% decreased level of prostate-specific antigen, compared with baseline. Associations between BR and different PET parameters were tested. A cutoff of at least a 30% decrease in PSMA total tumor volume (PSMA-TV) was used to define a PSMA response (PSMA-R) versus a PSMA nonresponse (PSMA-NR). Correlations between PSMA PET/CT response and BR were evaluated using the ϕ-coefficient. Associations between PET response and overall survival (OS) was tested using Cox regression and the Kaplan-Meier method. Results: Our cohort comprised 8 (22%) metastatic hormone-sensitive PCa and 29 (78%) mCRPC patients. Twenty-one patients received docetaxel treatment, and 16 received cabazitaxel (median, 6 cycles; interquartile range, 5-8 cycles). BR was found in 18 of 37 patients. Using PSMA total tumor volume, PSMA PET/CT response was concordant with BR in 35 of 37 patients (ϕ = 0.89, P < 0.0001). Eighteen of 37 patients had PSMA-R (6, complete response; 12, partial response), and 19 had PSMA-NR (17, progressive disease; 2, stable disease). After a median follow-up of 23 mo, there was a statistically significant longer OS for PSMA-R than for PSMA-NR (median OS not reached vs. 12 mo, respectively; hazard ratio, 0.10; 95% CI, 0.03-0.39; P = 0.001) for the entire population. Among the mCRPC subgroup, differences in OS were also observed (median, 22 vs. 12 mo, respectively; hazard ratio, 0.22; 95% CI, 0.06-0.82; P = 0.023), with a 12-mo OS rate of 100% for PSMA-R and 52% for PSMA-NR (P = 0.011). Conclusion: This retrospective analysis suggests that 68Ga-PSMA-11 PET/CT is a promising imaging modality for assessing response to taxane-based chemotherapy in metastatic PCa. Changes in PSMA expression might be used as a predictive biomarker for OS to help tailor individual therapy and select eligible patients for clinical trials.
引用
- Shagera QA, Artigas C, Karfis I, et al. 68Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy. J Nucl Med. 2021. PMID: 34772793. doi:10.2967/jnumed.121.263006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。